VivoSim Labs, Inc. (VIVS)
Oxford Ledge is still expanding full research coverage of VIVS. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
VivoSim Labs provides pharmaceutical testing services using proprietary three-dimensional human tissue models and bioprinting technology.
SEC filings
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-04-03
- S-1/A Amended registration statement 2026-03-31
- S-1 IPO / securities registration statement 2026-03-27
- 10-Q Quarterly financial report (unaudited) 2026-02-11
- 8-K Shareholder vote results; Financial statements and exhibits 2025-12-18
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for VIVS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open VIVS in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.